Eledon Pharmaceuticals Inc Stock News

On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025 IRVINE, Cal...

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering potential investment ideas and sparking community discussion. Aeluma, Inc. is a speculative microcap with game-changing semiconductor technology, a credible team, and significant grants, making it a strong buy. Big Yellow Group, despite macro pressures, shows steady revenue growth and strong cash generation, presentin...

Eledon Pharmaceuticals' lead candidate, tegoprubart, shows promise in improving kidney function post-transplant, potentially becoming the new standard-of-care over tacrolimus. With a significant total addressable market, tegoprubart could address over 25,000 new kidney transplant patients annually, translating to a $6B market opportunity. The upcoming Phase 2 study data in Q4 2025 is a critical...

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChic...

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.

Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.

Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $2...